Rossum, T.G.J. van

glycyrrhizin patient treatment hepatitis group study level liver hepatitis c effect cortisol liver disease glycyrrhetinic acid placebo chapter decrease baseline disease administration therapy plasma hepatocellular carcinoma 4 weeks glycyrrhetinic cirrhosis alt levels serum alt decrease glycyrrhizin treatment japan mechanism hepatitis c patients change analysis blood figure dosage interferon pharmacokinetic suzuki glycynhizin trial alt normalization side effects correlation carcinoma medication hepatocellular result difference percentage alt decrease randomized activity concentration aldosterone virus follow-up glycyrrhizine clearance normalization placebo group glycyrrhizin therapy efficacy percentage table european european patients value pressure ikeda k glycylthizin renin systolic blood pressure suzuki h suzuki y chayama k number cortisol levels dhea- limit